{"id":34480,"date":"2018-01-29T11:21:25","date_gmt":"2018-01-29T10:21:25","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=34480"},"modified":"2018-01-29T11:26:09","modified_gmt":"2018-01-29T10:26:09","slug":"jimenez-ad-novartis-le-farmaceutiche-devono-meno-esose","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/jimenez-ad-novartis-le-farmaceutiche-devono-meno-esose\/","title":{"rendered":"Jimenez (AD Novartis): Pharmaceuticals must be less expensive"},"content":{"rendered":"
\n

Less expensive pharmaceuticals<\/h1>\n<\/div>\n
\n

Novartis' number one believes that no one should be excluded from access to medicines for economic reasons<\/h2>\n<\/div>\n

Sunday 28\/01\/18 12:12 \u2013 RSI<\/span><\/a><\/p>\n

\u201cThe pharmaceutical industry should be closer to society also to improve its image\u201d. Thus the general manager of Novartis Joseph Jimenez from the columns of the NZZ am Sonntag. \u201cNo one should be \"\"<\/a>excluded from access to medicines only for financial reasons\u201d.<\/p>\n

The number one of the pharmaceutical giant from the Rhineland, although he resigned, also observed that "the threats in the electoral campaign of the then candidate for the White House, Donald Trump, at least had the effect of making pharmaceutical companies more careful when setting prices of their products".<\/p>\n

Novartis has thus, for example, established a price lower than the expectations of analysts and some shareholders for a drug against leukemia. However, the drug costs around 443,000 francs but recently "its price would have been between 600 and 700,000 dollars". Prices in the USA, Jimenez concluded, \u201cwill get closer and closer to the decidedly lower European prices\u201d.<\/p>\n

\n

Note: Joseph Jimenez<\/strong> Jr., 57 years old, Chief Executive Office Novartis, received in 2016 a total compensation of\u00a0SFr. 11,989,448<\/strong> (\u20ac 10,310,850.80 at today's exchange rate) \u2013 Source Bloomberg<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Farmaceutiche meno esose Il numero uno di Novartis ritiene che nessuno debba essere escluso dall’accesso alle medicine per questioni economiche domenica 28\/01\/18 12:12 – RSI “L\u2019industria farmaceutica dovrebbe essere pi\u00f9 vicina alla societ\u00e0 anche per migliorare la sua immagine”. Cos\u00ec il direttore generale di Novartis Joseph Jimenez dalle colonne della NZZ am Sonntag. \u201cNessuno dovrebbe …<\/p>","protected":false},"author":4,"featured_media":25276,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[51],"class_list":["post-34480","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-compenso-top-manager"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/34480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=34480"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/34480\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/25276"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=34480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=34480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=34480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}